Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

The prevalence of diabetes is increasing faster in some low-income countries than elsewhere in the world, generating concerns ...

Lexicon (LXRX) announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

The results showed that people who took sotagliflozin had a 23% lower risk of heart attacks, strokes, and death from ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

A recent study from the FINEARTS-HF trial revealed that finerenone, which is an oral mineralocorticoid receptor antagonist, ...

The results, published in The Lancet Diabetes and Endocrinology, showed that people in the sotagliflozin group had a 23 per ...

Is obesity a risk factor or a disease? This debate shapes treatments, policies, and eating disorder care. Explore its impact ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Sotagliflozin belongs to a class of medications called gliflozins that help lower blood sugar levels by preventing the ...